# BCD-217

Source: https://onco.cc/drugs/bcd-217/  
OnCo record `bcd-217` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BCD-217 is an experimental investigational agent whose form is not stated in the registry from Biocad in phase 3 trials for melanoma, aimed at PD-1 and CTLA-4.

## Summary

BCD-217 is an investigational agent whose form is not stated in the registry developed by Biocad. Its targets are PD-1 and CTLA-4. ClinicalTrials.gov describes the intervention as: Subject recieves BCD-217 0.2 mL/kg, which is equivalent to 1 mg/kg nurulimab + 3 mg/kg prolgolimab, as an intravenous infusion once every 3 weeks (Q3W) simultaneously with placebo, a total of 4 intravenous infusions. Beginning with the 5th. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT05732805 (A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma) and NCT05751928 (A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma), in melanoma. The largest, NCT05751928, plans to enrol 411 participants (actual) with primary completion expected 2027-01. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Also known as: nurulimab+prolgolimab
- Tags: pipeline; ctgov-ingest
- Modality: antibody combination (nurulimab and prolgolimab; INN stem -mab; form not stated in the registry record)
- Mechanism: Investigational agent whose form is not stated in the registry directed at PD-1 and CTLA-4, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of BCD-217: https://clinicaltrials.gov/search?intr=BCD-217
- Sponsor page: https://biocad.ru/products

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- targets: [CTLA-4](https://onco.cc/targets/ctla4/), [PD-1](https://onco.cc/targets/pd1/)
- companies: [Biocad](https://onco.cc/companies/biocad/)
- trials: [A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma](https://onco.cc/trials/nct05732805/), [A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma](https://onco.cc/trials/nct05751928/)

---
JSON: https://onco.cc/api/v1/entities/bcd-217.json